ArticleDermatologic therapy2020
Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".
Article in Dermatologic therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.Dermatologic therapy · 2020Pooled it
- Use of biologics in patients with psoriasis - A retrospective analysis based on real-world data.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.Advances in experimental medicine and biology · 2023Article
- Biologics for Psoriasis during the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- Generalized pustular psoriasis following COVID-19.Dermatologic therapy · 2021Article
- Biologics for Psoriasis During the COVID-19 Pandemic.Frontiers in medicine · 2021Review
- The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul.Dermatologic therapy · 2021Article
- COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.Dermatologic therapy · 2020Article
- Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein:RSC advances · 2020Article
- COVID-19 and dermatology: a comprehensive guide for dermatologists.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Review
- Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?Dermatologic therapy · 2020Article
- Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".Dermatologic therapy · 2020Article
- Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.Dermatologic therapy · 2020Article
- COVID-19 and psoriasis: Should we fear for patients treated with biologics?Dermatologic therapy · 2020Review
- Comment on "Antipsoriatic treatments during COVID-19 outbreak".Dermatologic therapy · 2020Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.